Search research articles
Contact Us
Filters
Showing results (181-190 of 196) with videos related to
Page
of 20
Sort By:
International Journal of Cancer
|
March 16, 2026
Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma
Zhixiong Cai, Liman Qiu, Ling Li, et al.
BMC Cancer
|
December 5, 2021
Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China
Yifan Chen, Hongzhi Liu, Jinyu Zhang, et al.
BMC Cancer
|
July 21, 2021
Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study
Hongzhi Liu, Lianku Lin, Ziguo Lin, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2024
Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8<sup>+</sup>CD69<sup>+</sup> T cells
Shichuan Tang, Ruijing Tang, Geng Chen, et al.
Bioscience Trends
|
April 23, 2025
Platelet count as a double-edged sword: The impact of thrombocytosis and thrombocytopenia on long-term outcomes after hepatic resection for hepatocellular carcinoma
Xuedong Wang, Pengfei Wang, Bingjun Tang, et al.
Cancer Letters
|
January 25, 2024
Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study
Yangyang Wang, Xu Sun, Cao Chen, et al.
Hepatology International
|
October 18, 2022
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
Zhenbin Ding, Hong Wu, Yongyi Zeng, et al.
Frontiers in Immunology
|
May 14, 2023
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
Yangxun Pan, Xiaodong Zhu, Jianwei Liu, et al.
Lancet (London, England)
|
October 22, 2025
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
Zheng Wang, Jia Fan, Shaolai Zhou, et al.
Gut
|
October 28, 2025
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
Shichuan Tang, Tingfeng Huang, Ruijing Tang, et al.
Page
of 20
Search research articles
Search
Showing results (181-190 of 196) with videos related to
Sort By:
Page
of 20
International Journal of Cancer
|
March 16, 2026
Sequential personalized neoantigen vaccination following first-line treatments demonstrates safety and efficacy in advanced hepatocellular carcinoma
Zhixiong Cai, Liman Qiu, Ling Li, et al.
BMC Cancer
|
December 5, 2021
Prognostic value and predication model of microvascular invasion in patients with intrahepatic cholangiocarcinoma: a multicenter study from China
Yifan Chen, Hongzhi Liu, Jinyu Zhang, et al.
BMC Cancer
|
July 21, 2021
Impact of surgical margin width on long-term outcomes for intrahepatic cholangiocarcinoma: a multicenter study
Hongzhi Liu, Lianku Lin, Ziguo Lin, et al.
Journal for Immunotherapy of Cancer
|
December 18, 2024
Personalized neoantigen hydrogel vaccine combined with PD-1 and CTLA-4 double blockade elicits antitumor response in liver metastases by activating intratumoral CD8<sup>+</sup>CD69<sup>+</sup> T cells
Shichuan Tang, Ruijing Tang, Geng Chen, et al.
Bioscience Trends
|
April 23, 2025
Platelet count as a double-edged sword: The impact of thrombocytosis and thrombocytopenia on long-term outcomes after hepatic resection for hepatocellular carcinoma
Xuedong Wang, Pengfei Wang, Bingjun Tang, et al.
Cancer Letters
|
January 25, 2024
Optimizing hepatocellular carcinoma disease staging systems by incorporating tumor micronecrosis: A multi-institutional retrospective study
Yangyang Wang, Xu Sun, Cao Chen, et al.
Hepatology International
|
October 18, 2022
Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures
Zhenbin Ding, Hong Wu, Yongyi Zeng, et al.
Frontiers in Immunology
|
May 14, 2023
Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study
Yangxun Pan, Xiaodong Zhu, Jianwei Liu, et al.
Lancet (London, England)
|
October 22, 2025
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
Zheng Wang, Jia Fan, Shaolai Zhou, et al.
Gut
|
October 28, 2025
EASL 2025 indications revisited: phase-specific outcomes with and without nucleos(t)ide analogue therapy in chronic hepatitis B virus infection
Shichuan Tang, Tingfeng Huang, Ruijing Tang, et al.
Page
of 20